BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31951778)

  • 1. Aclidinium bromide and formoterol fumarate for the maintenance treatment of chronic obstructive pulmonary disease.
    Haley R; Gupta N; Sethi S
    Expert Rev Clin Pharmacol; 2020 Feb; 13(2):103-113. PubMed ID: 31951778
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
    D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
    Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.
    Di Marco F; Santus P; Scichilone N; Solidoro P; Contoli M; Braido F; Corsico AG
    Respir Med; 2017 Apr; 125():49-56. PubMed ID: 28340862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
    Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base.
    D'Urzo AD; Singh D; Donohue JF; Chapman KR
    Ther Adv Respir Dis; 2019; 13():1753466619850725. PubMed ID: 31096854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease.
    D'Urzo T; Donohue JF; Price D; Miravitlles M; Kerwin E
    Expert Rev Respir Med; 2015 Oct; 9(5):519-32. PubMed ID: 26366803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.
    Babu KS; Morjaria JB
    Ther Adv Respir Dis; 2015 Apr; 9(2):56-68. PubMed ID: 25754881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.
    Rhee CK; Yoshisue H; Lad R
    Adv Ther; 2019 Mar; 36(3):495-519. PubMed ID: 30742242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond.
    Rabe KF
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):685-698. PubMed ID: 28443352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β
    Siddiqui MK; Shukla P; Jenkins M; Ouwens M; Guranlioglu D; Darken P; Biswas M
    Ther Adv Respir Dis; 2019; 13():1753466619894502. PubMed ID: 31868101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New opportunities of dual bronchodilation therapy for patients with chronic obstructive pulmonary disease.
    Avdeev SN; Trushenko NV
    Ter Arkh; 2019 Mar; 91(3):76-85. PubMed ID: 31094464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis.
    Miravitlles M; Chapman KR; Chuecos F; Ribera A; Gil EG
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2041-53. PubMed ID: 27621610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT.
    D'Urzo AD; Singh D; Donohue JF; Kerwin EM; Ribera A; Molins E; Chuecos F; Jarreta D; Gil EG
    Int J Chron Obstruct Pulmon Dis; 2019; 14():479-491. PubMed ID: 30880938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
    Malerba M; Radaeli A; Santini G; Morjaria J; Mores N; Mondino C; Macis G; Montuschi P
    Expert Opin Drug Discov; 2018 Jun; 13(6):563-577. PubMed ID: 29616842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.
    Donohue JF; Soong W; Wu X; Shrestha P; Lei A
    Respir Med; 2016 Jul; 116():41-8. PubMed ID: 27296819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.
    Sethi S; Kerwin E; Watz H; Ferguson GT; Mroz RM; Segarra R; Molins E; Jarreta D; Garcia Gil E
    Int J Chron Obstruct Pulmon Dis; 2019; 14():667-682. PubMed ID: 30962681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
    Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease.
    D'Urzo A; Rennard S; Kerwin E; Donohue JF; Lei A; Molins E; Leselbaum A
    Respir Med; 2017 Apr; 125():39-48. PubMed ID: 28340861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.
    Rogliani P; Matera MG; Ritondo BL; De Guido I; Puxeddu E; Cazzola M; Calzetta L
    Pulm Pharmacol Ther; 2019 Dec; 59():101841. PubMed ID: 31520718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease.
    Cazzola M; Rogliani P; Matera MG
    Expert Opin Pharmacother; 2013 Apr; 14(6):775-81. PubMed ID: 23472632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.